Intermittent theta burst stimulation (iTBS) is an emerging non-invasive neuron regulation technique, which is widely used in neuropsychiatry for a variety of diseases and is widely accepted by patients due to its non-invasive, operable and relatively precise localization. Combining the results of previous studies and our group's previous research, sixty qualified PD patients would be enrolled to conduct a prospective single-center randomized double-blind sham controlled clinical trial to verify the long-term curative effects of iTBS treatment protocol and explore the neuron-protection of iTBS on neuronal loss of PD patients.

Inclusion Criteria:

• Meet the revised clinical diagnostic criteria for Parkinson's disease of the Movement Disorder Society (MDS) International (2015 version).
• aged >20 years and <80 years, regardless of gender.
• 2 ≤ Hoehn-Yahr stage≤ 4.
• Maintain medication stability during the study period.
• Good compliance, written informed consent, and consent for long-term interventional treatment with iTBS.

Exclusion Criteria:

• Patients with severe neuropsychiatric disorders or previous history of severe neurological disorders (e.g., epilepsy, cerebrovascular accidents, etc.) or history of traumatic brain injury or brain surgery.
• Patients with significant cognitive impairment (MMSE < 24) or inability to complete questionnaires independently.
• Prior treatment with TMS, DBS or SCS.
• Severe physical illness and any physical illness that can precipitate epilepsy or intracranial hypertension, including cardiovascular and respiratory disease.
• Have human implantable materials such as intracranial stents, pacemakers, coronary stents, cochlear implants, etc.
• Are currently taking other investigational drugs.
• Any other condition that the investigator deems unsuitable for participation in this study.

No individual participant data (IPD) was available to other researchers.